An Update on Coronavirus Disease 2019 (COVID-19) and Pregnancy

Physiologic, mechanical and immunologic alterations in pregnancy could potentially affect susceptibility to and severity of COVID-19 during pregnancy. Due to lack of comparable incidence data and challenges with disentangling differences in susceptibility from different exposure risks, data are insufficient to determine whether pregnancy increases susceptibility to SARS-CoV-2 infection. Data support pregnancy as a risk factor for severe disease associated with COVID-19; some of the best evidence comes from the Centers for Disease Control and Prevention ’s (CDC’s) COVID-19 surveillance system, which reported that pregnant persons were more likely to be admitted to an intensive care unit (ICU), require invasive ventilation, require extracorporeal membrane oxygenation, and die compared with nonpregnant women of reproductive age.
Source: American Journal of Obstetrics and Gynecology - Category: OBGYN Authors: Tags: Expert Review Source Type: research

Related Links:

BJOG. 2021 Oct 23. doi: 10.1111/1471-0528.16981. Online ahead of print.ABSTRACTUnlike many viral infections such as influenza, and the two previous incarnations of the coronavirus, SARS and MERS, Covid-19 originally appeared to be of similar severity, after adjusting for age, BMI and other co-morbidities, in the pregnant as in the non-pregnant population. Worryingly the paper from the Italian Obstetric Surveillance System COVID-19 Working Group (p …), suggests that, in pregnancy, the virus may be getting more virulent with the advent of newer variants. Specifically the need for ventilation or ICU admission was signi...
Source: BJOG : An International Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Source Type: research
NEW BRUNSWICK, N.J., October 21, 2021 – Johnson &Johnson (the Company) today announced that the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), has recommended its COVID-19 vaccine as a booster for all eligible individuals who receive an authorized COVID-19 vaccine. “Today’s recommendation supports the use of the Johnson &Johnson COVID-19 vaccine as a booster for eligible individuals in the U.S. regardless of which vaccine they initially receive,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
CONCLUSIONS: Our study, which is the largest prospective consecutive cohort to date, has confirmed that advanced maternal age, diabetes, hypertension, obesity, very high social vulnerability, and low socioeconomic status are risk factors of COVID-19-related mortality This article is protected by copyright. All rights reserved.PMID:34672382 | DOI:10.1002/uog.24797
Source: The Ultrasound Review of Obstetrics and Gynecology - Category: Radiology Authors: Source Type: research
NEW BRUNSWICK, N.J., October 20, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson &Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson &Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine. The Johnson &Johnson booster shot will be the same formulation and dosage as the primary shot. The EUA follows a unanimous recommendat...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Latest News Source Type: news
Neuropharmacology. 2021 Oct 16;201:108841. doi: 10.1016/j.neuropharm.2021.108841. Online ahead of print.ABSTRACTA strong association between perinatal viral infections and neurodevelopmental disorders has been established. Both the direct contact of the virus with the developing brain and the strong maternal immune response originated by viral infections can impair proper neurodevelopment. Coronavirus disease 2019 (COVID-19), caused by the highly-infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently responsible for a large global outbreak and is a major public health issue. While initial stu...
Source: Neuropharmacology - Category: Drugs & Pharmacology Authors: Source Type: research
In conclusion, we consider pregnant women a high-risk group of patients towards a possible SARS-CoV-2 infection, especially those who present with conditions such as gestational hypertension or obesity; moreover, we think that SARS-CoV-2 infection could increase the possibilities of having an abruptio placentae, although this result was found in only a few women, so it requires further confirmation.
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
CONCLUSION: Pregnant women were not more likely to be infected with SARS-CoV-2. Still, pregnant women with COVID-19, especially those born outside of Scandinavia, were more likely to be hospitalized.PMID:34657368 | DOI:10.1111/1471-0528.16969
Source: BJOG : An International Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Source Type: research
NEW BRUNSWICK, N.J., October 15, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 19-0 to recommend Emergency Use Authorization (EUA) for a booster dose of the Johnson &Johnson COVID-19 vaccine for adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine. The vote was based on findings from two Company clinical trials, including the Phase 3 ENSEMBLE 2 study, which evaluated a booster dose of the Johnson &J...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
We report an updated literature review of current information and evidence available to aid in the decision whether to vaccinate against COVID-19 currently being made by pregnant individuals and their healthcare providers so that they are able to make a well-informed recommendation and decision.PMID:34651406 | DOI:10.1111/1471-0528.16973
Source: BJOG : An International Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Source Type: research
Obstet Gynecol. 2021 Oct 13. doi: 10.1097/AOG.0000000000004621. Online ahead of print.NO ABSTRACTPMID:34644272 | DOI:10.1097/AOG.0000000000004621
Source: Obstetrics and Gynecology - Category: OBGYN Authors: Source Type: research
More News: Allergy & Immunology | Centers for Disease Control and Prevention (CDC) | Coronavirus | COVID-19 | Intensive Care | OBGYN | Pregnancy | SARS | Women